LABFF
Laboratorios Farmaceuticos Rovi, S.A./ADR
$90.61
0.00%
No data for this timeframe.
Vol
Analyst Ratings
4Strong Buy
6Buy
6Hold
0Sell
0Strong Sell
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
No SEC filing reports analyzed yet. Reports are generated when new filings are detected and processed by the LLM pipeline.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution: 63% buy across 16 analysts — 4 strong buy, 6 buy, 6 hold, 0 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.8B | 4.1% | — |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.9B | 18.0% | — |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 6 | 6 | 0 | 0 | 63% | |
| May 1, 2026 | 4 | 8 | 4 | 0 | 0 | 75% | |
| Apr 1, 2026 | 4 | 8 | 4 | 0 | 0 | 75% | |
| Mar 1, 2026 | 5 | 8 | 3 | 0 | 0 | 81% | |
| Feb 1, 2026 | 5 | 8 | 3 | 0 | 0 | 81% | |
| Jan 1, 2026 | 4 | 9 | 3 | 0 | 0 | 81% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 26, 2026
Clinical Trial
Clinical Study to Evaluate PRO-169 for Diabetic Macular Edema
Phase Phase 3 — COMPLETED
Apr 24, 2026
Clinical Trial
Efficacy and Safety of Etoricoxib+Diacerein in Osteoarthritis.
Phase Phase 3 — COMPLETED